Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes

Digestive Diseases and Sciences

Volumn 42, Issue 7, 1997, Pages 1542-1548

  Bousvaros, Athos ^b   Stevens, A Christopher ^a   Strom, Terry B ^b   Murphy, J ^b   Lamont, J Thomas ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

Diphtheria toxin; Interleukin 2; Lamina propria; Lymphocytes; T cells

Indexed keywords

DENILEUKIN DIFTITOX; GAMMA INTERFERON; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR;

ARTICLE; ENTERITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; INFLAMMATION; LAMINA PROPRIA; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

DIPHTHERIA TOXIN; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTOXINS; INTERLEUKIN-2; INTESTINAL MUCOSA; LYMPHOCYTE ACTIVATION; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 0030746198     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018891432581     Document Type: Article

References (37)

1. Schreiber S, Raedler A, Stenson WF, MacDermott RP: The role of the mucosal immune system in inflammatory bowel disease. Gastroenterol Clin North Am 21:451-502, 1992
2. Peppercorn MA: Advances in drug therapy for inflammatory bowel disease. Ann Intern Med 112:50-60, 1990
3. Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS: Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 302:981-987, 1980
4. Lichtiger S, Present DH: Preliminary report: Cyclosporin in treatment of severe active ulcerative colitis. Lancet 336:16-19, 1990
5. Williams DP, Parker K, Bacha P, Bishai W, Borowski M, Genbauffe F, Strom TB, Murphy JR: Diphtheria toxin receptor binding domain substitution with interleukin-2. Protein Eng 1:493-498, 1987
6. Proujansky R, Carpenter A: Soluble interleukin-2 receptor as a marker of lymphocyte activation in childhood Crohn's disease. J Pediatr Gastroenterol Nutr 13:277-280, 1991
7. Schreiber S, MacDermott RP, Raedler A, Pinnau R, Bertovich MJ, Nash GS: Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease. Gastroenterology 101:1020-1030, 1991
8. Matsuura T, West GA, Youngman KR, Klein JS, Fiocchi C: Immune activation genes in inflammatory bowel disease. Gastroenterology 104:448-458, 1993
9. Choy MY, Walker-Smith JA, Williams CB, Macdonald TT: Differential expression of CD25 on lamina propria T cells and macrophages in Crohn's disease and ulcerative colitis. Gut 31:1365-1370, 1990
10. Mueller CH, Knoflach P, Zielinski CC: T cell activation in Crohn's disease: Increased levels of soluble interleukin-2 receptor. Gastroenterology 98:639-646, 1990
11. Bull DM, Bookman MA: Isolation and functional characterization of human intestinal mucosal lymphoid cells. J Clin Invest 59:966-971, 1977
12. Fiocchi C, Battisto JR, Farmer RG: Gut mucosal lymphocytes in inflammatory bowel disease. Dig Dis Sci 9:705-717, 1979
13. Smith KA: Interleukin 2: Inception, impact, and implications. Science 240:1169-1176, 1988
14. Pallone F, Fais S, Squarcia O, Biancone L, Pozzilli P, Boirivant M: Activation of peripheral blood and intestinal lamina propria lymphocytes in Crohn's disease. Gut 28:745-751, 1987
15. Giannini G, Rappuoli R, Ratti G: The amino-acid sequence of two non-toxic mutants of diphtheria toxin: CRM45 and CRM197. Nucleic Acids Res 12:4063-4069, 1984
16. Williams DP, Snider CE, Strom TB, Murphy JR: Structure/ function analysis of interleukin-2-toxin (DAB-486-IL-2). J Biol Chem 265:11885-11889, 1990
17. vanderSpek JC, Mindell JA, Finkelstein A, Murphy JR: Structure/function analysis of the transmembrane domain of DAB389-interleukin-2, an interleukin-2 receptor-targeted fusion toxin. The amphipathic helical region of the transmembrane domain is essential for the efficient delivery of the catalytic domain to the cytosol of target cells. J Biol Chem 268:12077-12082, 1993
18. Taniguchi T, Minani Y: The IL-2/IL-2 receptor system: A current overview. Cell 73:5-8, 1993
19. Waters CA, Schimke PA, Snider CE, Itoh K, Smith KA, Nichols JC, Strom TB, Murphy JR: Interleukin 2 receptor targeted cytotoxicity. Receptor binding requirements for entry of a diphtheria toxin-related interleukin 2 fusion protein into cells. Eur J Immunol 20:785-791, 1990
20. 486IL-2) results in specific deletion of antigen-activated T-cell clones. J Immunol 145:3535-3539, 1990
21. 486IL-2) in hematologic malignancies expressing the IL-2 receptor. Blood 79:2547-2554, 1992
22. 486IL-2 in advanced mycosis fungoides and the Sezary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 84:1765-1774, 1994
23. 486IL-2) in hematologic malignancies: complete response in a patient with Hodgkin's disease refractory to chemotherapy. Cancer 73:1276-1285, 1994
24. Kiyokawa T, Shirono K, Hattori T, Nishimura H, Yamaguchi K, Nichols JC, Strom TB, Murphy JR, Takatsuki K: Cytotoxicity of interleukin-2 toxin toward lymphocytes from patients with adult T-cell leukemia. Cancer Res 49:4042-4046, 1989
25. 486IL-2 in hematologic cancers. Cancer Res 53:3930-3934, 1993
26. Hesketh P, Caguioa P, Koh H, Dewey H, Facada A, McCaffrey R, Parker K, Nylen P, Woodworth T: Clinical activity of a cytotoxic fusion protein in the treatment of cutaneous T-cell lymphoma. J Clin Oncol 11:1682-1690, 1993
27. 486IL-2) in patient with chronic lymphocytic leukaemia. Lancet 337:1124-1125, 1991
28. 486IL-2 fusion toxin in refractory rheumatoid arthritis. Arthritis Rheum 36:1223-1233, 1993
29. 389IL-2 fusion toxin evaluation in lymphoma clinical trials (meeting abstract). Proc Annu Meet Am Assoc Cancer Res 34:A1237, 1993
30. Strom TB, Kelley VR, Murphy JR, Nichols J, Woodworth TG: Interleukin-2 receptor directed therapies: Antibody or cytokine-based targeting molecules. Annu Rev Med 44:343-353, 1993
31. 389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1:442-447, 1995
32. 389IL-2 for the treatment of interleukin-2 receptor (IL-2R) expressing hematologic neoplasms. Blood 86(suppl 1):274A, 1995
33. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP: Increased interleukin-2 mRNA in the intestinal mucosal lesions of Crohn's disease hut not ulcerative colitis. Gastroenterology 102:1620-1627, 1992
34. Fais S, MR Capohianchi Pallone F, DiMarco P, Boirivant M, Dianzani F, Torsoli A: Spontaneous release of interferon γ by intestinal lamina propria lymphocytes in Crohn's disease. Gut 32:403-407, 1991
35. Fuss IJ, Neurath M, Klein JS, de la Motte C, Strong SA, Fiocchi C, Strober W: Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261-1270, 1996
36. Niessner M, Volk BA: Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reverse transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol 101:428-435, 1995
37. Gilberts EC, Greenstein AJ, Katsel P, Harpaz N, Greenstein RJ: Proc Natl Acad Sci 91:12721-12724, 1991